US2018256603A1PendingUtilityA1

Compositions comprising triterpenoids

50
Assignee: REGENERA PHARMA LTDPriority: Sep 24, 2015Filed: Sep 22, 2016Published: Sep 13, 2018
Est. expirySep 24, 2035(~9.2 yrs left)· nominal 20-yr term from priority
Inventors:Zadik HazanKonstantin AdamskyAndre C. B. LucassenNurit Novak
A61K 45/06A61K 31/745A61P 9/10A61K 31/575A61K 2300/00A61K 31/122A61K 36/22A61K 31/56A61K 31/569A61K 31/047
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating stroke or trauma and side effects related thereto.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition comprising a combination of at least one triterpenoic acid and at least one neutral triterpenoid, and a pharmaceutically acceptable carrier, wherein the triterpenoic acid is selected from masticadienonic acid (MDA), isomasticadienonic acid (IMDA), or both, and wherein the neutral triterpenoid is selected from (8R)-3-beta, 8-dihydroxypolypoda-13E,17E,21-triene (NF-1), (8R)-3-Oxo-8-hydroxypolypoda-13E,17E,21-triene (NF-2), or both. 
     
     
         2 . The pharmaceutical composition of  claim 1 , further comprising at least one additional triterpenoic acid selected from the group consisting of: masticadienolic acid (MLA), isomasticadienolic acid (IMLA), 3-O-acetyl masticadienolic acid, 3-O-acetyl epimasticadienolic acid, 3-O-acetyl isomasticadienolic acid, 3-O-acetyl epi-isomasticadienolic acid, oleanonic acid (OA), moronic acid (MA), or any combination thereof. 
     
     
         3 . The pharmaceutical composition of  claim 1 , further comprising at least one additional neutral triterpenoid selected from the group consisting of Oleanonic aldehyde (NF-3), Tirucallol (NF-4), 28-hydroxylup-20(29)-en-3-one (NF-A), 28-hydroxy-beta-amyrone (NF-B), or any combination thereof. 
     
     
         4 . The pharmaceutical composition of  claim 3 , further comprising 20-hydroxydammar-24-en-3-one (NF-P). 
     
     
         5 . The pharmaceutical composition of  claim 3 , wherein at least one of said additional neutral triterpenoids is selected from NF-3 and NF-4. 
     
     
         6 . The pharmaceutical composition of  claim 3 , comprising at least two additional neutral triterpenoids. 
     
     
         7 . The pharmaceutical composition of  claim 1 , substantially devoid of essential oils. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein at least one triterpenoic acid is obtained from a plant source. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein at least one neutral triterpenoid is obtained from a plant source. 
     
     
         10 . The pharmaceutical composition according to  claim 8 , wherein said plant source comprises mastic gum. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein at least one triterpenoic acid is obtained via chemical synthesis. 
     
     
         12 . The pharmaceutical composition of  claim 1 , wherein at least one neutral triterpenoid is obtained via chemical synthesis. 
     
     
         13 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutically acceptable carrier comprises at least one oil. 
     
     
         14 . The pharmaceutical composition of  claim 1 , in a form suitable for administration by a route selected from the group consisting of parenteral, transdermal, oral and topical. 
     
     
         15 . (canceled) 
     
     
         16 . The pharmaceutical composition according to  claim 3 , comprising pharmaceutically active ingredients consisting essentially of: MA, OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3, NF-4, NF-A and NF-B; and the pharmaceutically acceptable carrier. 
     
     
         17 . The pharmaceutical composition according to  claim 3 , comprising pharmaceutically active ingredients consisting essentially of: MA, OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3 and NF-4; and the pharmaceutically acceptable carrier. 
     
     
         18 . The pharmaceutical composition according to  claim 3 , comprising pharmaceutically active ingredients consisting essentially of: OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3, NF-4, NF-A and NF-B; and a pharmaceutically acceptable carrier. 
     
     
         19 . The pharmaceutical composition according to  claim 3 , comprising pharmaceutically active ingredients consisting essentially of: OA, MDA, IMDA, 3-O-acetyl masticadienolic acid, 3-O-acetyl isomasticadienolic acid, NF-1, NF-2, NF-3 and NF-4; and a pharmaceutically acceptable carrier. 
     
     
         20 . The pharmaceutical composition according to  claim 4 , comprising pharmaceutically active ingredients consisting essentially of: MDA, IMDA, MLA, IMLA, NF-1, NF-2, NF-3, NF-4, NF-P, NF-A and NF-B; and a pharmaceutically acceptable carrier. 
     
     
         21 . The pharmaceutical composition according to  claim 3 , comprising pharmaceutically active ingredients consisting essentially of: MDA, IMDA, NF-1, NF-2, NF-3 and NF-4; and the pharmaceutically acceptable carrier. 
     
     
         22 . The pharmaceutical composition according to  claim 1 , comprising pharmaceutically active ingredients consisting essentially of: of MDA, IMDA, NF-1, NF-2; and the pharmaceutically acceptable carrier. 
     
     
         23 . A method of treating a stroke or trauma, the method comprising administering to a subject the pharmaceutical composition of  claim 1 . 
     
     
         24 . (canceled) 
     
     
         25 . The method according to  claim 23 , wherein treating a stroke or trauma comprises treating side effects related thereto. 
     
     
         26 . The method according to  claim 25 , wherein the trauma is a traumatic brain injury (TBI). 
     
     
         27 - 29 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.